Seroquel (quetiapine fumarate)
In July 2012, AstraZeneca received a civil investigative demand from the Office of the Attorney General for the State of Texas in connection with an investigation related to sales and marketing activities potentially involving Seroquel.
In June 2012, AstraZeneca executed an agreement to settle and dismiss the claims brought by the New Mexico State Attorney General regarding allegedly false and/or misleading statements made by AstraZeneca in the marketing and promotion of Seroquel and reached an agreement in principle to settle and dismiss similar claims brought by the Utah State Attorney General, pending documentation. Provisions have been taken in the second quarter. In July 2012, AstraZeneca also reached an agreement in principle to settle and dismiss similar claims brought by the South Carolina State Attorney General, pending documentation. A provision will be taken in July.